Decrease of obesity by allantoin via imidazoline Ireceptor activation in high fat diet-fed mice

Evidence-based Complementary and Alternative Medicine

Volumn 2013, Issue , 2013, Pages

  Chung, Hsien Hui ^a   Lee, Kung Shing ^b   Cheng, Juei Tang ^a,c  

^a NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^b KAOHSIUNG MUNICIPAL HSIAO KANG HOSPITAL   (Taiwan)

^c CHANG JUNG CHRISTIAN UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ALLANTOIN; EFAROXAN; IMIDAZOLINE I1 RECEPTOR; NEUROPEPTIDE Y;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY WEIGHT; CALORIC INTAKE; CONTROLLED STUDY; HYPERLEPTINEMIA; LIPID DIET; MALE; MOUSE; NONHUMAN; OBESITY; PRIORITY JOURNAL; WHITE ADIPOSE TISSUE;

EID: 84877258061     PISSN: 1741427X     EISSN: 17414288     Source Type: Journal    
DOI: 10.1155/2013/589309     Document Type: Article

References (47)

1. Hutcheson R., Rocic P., The metabolic syndrome, oxidative stress, environment, and cardiovascular disease: the great exploration. Experimental Diabetes Research 2012 2012 13 271028 10.1155/2012/271028
2. Koebnick C., Smith N., Huang K., Martinez M. P., Clancy H. A., Kushi L. H., The prevalence of obesity and obesity-related health conditions in a large, multiethnic cohort of young adults in California. Annals of Epidemiology 2012 22 9 609 616
3. Woodhouse R., Obesity in art-a brief overview. Frontiers of Hormone Research 2008 36 271 286 2-s2.0-43049086378 10.1159/000115370
4. Haslam D. W., James W. P. T., Obesity. The Lancet 2005 366 9492 1197 1209 2-s2.0-25844457693 10.1016/S0140-6736(05)67483-1 (Pubitemid 41393598)
5. Müller M. J., Lagerpusch M., Enderle J., Schautz B., Heller M., Bosy-Westphal A., Beyond the body mass index: tracking body composition in the pathogenesis of obesity and the metabolic syndrome. Obesity Reviews 2012 13 supplement 2 6 13
6. Novak N. L., Brownell K. D., Obesity: a public health approach. The Psychiatric Clinics of North America 2011 34 4 895 909
7. Dubnov-Raz G., Berry E. M., The dietary treatment of obesity. The Medical Clinics of North America 2011 95 5 939 952
8. Scheen A. J., Ernest P., New antiobesity agents in type 2 diabetes: overview of clinical trials with sibutramine and orlistat. Diabetes and Metabolism 2002 28 6, part 1 437 445 2-s2.0-0036943785 (Pubitemid 36077145)
9. Mollah M. L., Kim G. S., Moon H. K., Chung S. K., Cheon Y. P., Kim J. K., Kim K. S., Antiobesity effects of wild ginseng (Panax ginseng C.A. meyer) mediated by PPAR- γ GLUT4 and LPL in ob/ob mice. Phytotherapy Research 2009 23 2 220 225 2-s2.0-59449090299 10.1002/ptr.2593
10. Vasudeva N., Yadav N., Sharma S. K., Natural products: a safest approach for obesity. The Chinese Journal of Integrative Medicine 2012 18 6 473 480
11. Sagara K., Ojima M., Suto K., Yoshida T., Quantitative determination of allantoin in Dioscorea rhizome and an oriental pharmaceutical preparation, Hachimi-Gan, by high-performance liquid chromatography. Planta Medica 1989 55 1, article 93 2-s2.0-0024602301
12. Shestopalov A. V., Shkurat T. P., Mikashinovich Z. I., Kryzhanovskaia I. O., Bogacheva M. A., Lomteva S. V., Prokof'ev V. P., Gus'kov E. P., Biological functions of allantoin. Izvestiia Akademii Nauk Seriia Biologicheskaia 2006 5 541 545 2-s2.0-39049186158
13. Lee M. Y., Lee N. H., Jung D., Lee J. A., Seo C. S., Lee H., Kim J. H., Shin H. K., Protective effects of allantoin against ovalbumin (OVA)-induced lung inflammation in a murine model of asthma. International Immunopharmacology 2010 10 4 474 480 2-s2.0-77949492200 10.1016/j.intimp.2010.01.008
14. Chang W. C., Yu Y. M., Wu C. H., Tseng Y. H., Wu K. Y., Reduction of oxidative stress and atherosclerosis in hyperlipidemic rabbits by Dioscorea rhizome. The Canadian Journal of Physiology and Pharmacology 2005 83 5 423 430 2-s2.0-22344458094 10.1139/y05-028 (Pubitemid 41003317)
15. Wang T., Choi R. C., Li J., Trillin, a steroidal saponin isolated from the rhizomes of Dioscorea nipponica, exerts protective effects against hyperlipidemia and oxidative stress. Journal of Ethnopharmacology 2012 139 1 214 220
16. Yang T. T., Chiu N. H., Chung H. H., Hsu C. T., Lee W. J., Cheng J. T., Stimulatory effect of allantoin on imidazoline i1 receptors in animal and cell line. Hormone and Metabolic Research 2012 44 12 879 884
17. Chung H. H., Yang T. T., Chen M. F., Chou M. T., Cheng J. T., Improvement of hyperphagia by activation of cerebral I(1)-imidazoline receptors in streptozotocin-induced diabetic mice. Hormone and Metabolic Research 2012 44 9 645 649
18. Matsumoto K., Watanabe Y., Yokoyama S. I., Okara, soybean residue, prevents obesity in a diet-induced murine obesity model. Bioscience, Biotechnology and Biochemistry 2007 71 3 720 727 2-s2.0-33947576447 10.1271/bbb.60563 (Pubitemid 46481448)
19. Bartolomucci A., Bresciani E., Bulgarelli I., Rigamonti A. E., Pascucci T., Levi A., Possenti R., Torsello A., Locatelli V., Muller E. E., Moles A., Chronic intracerebroventricular injection of TLQP-21 prevents high fat diet induced weight gain in fast weight-gaining mice. Genes and Nutrition 2009 4 1 49 57 2-s2.0-60749128013 10.1007/s12263-009-0110-0
20. Niu C. S., Wu H. T., Cheng K. C., Lin K. C., Chen C. T., Cheng J. T., A novel mechanism for decreasing plasma lipid level from imidazoline I-1 receptor activation in high fat diet-fed mice. Hormone and Metabolic Research 2011 43 7 458 463 2-s2.0-79958771832 10.1055/s-0031-1275325
21. Yang P. S., Wu H. T., Chung H. H., Rilmenidine improves hepatic steatosis through p38-dependent pathway to higher the expression of farnesoid X receptor. Naunyn-Schmiedeberg's Archives of Pharmacology 2012 385 1 51 56
22. Gongadze N. V., Antelava N. A., Kezeli T. D., Imidazoline receptors. Georgian medical news 2008 160-161 44 47 2-s2.0-58149197844
23. Head G. A., Mayorov D. N., Imidazoline receptors, novel agents and therapeutic potential. Cardiovascular and Hematological Agents in Medicinal Chemistry 2006 4 1 17 32 2-s2.0-33646381125 10.2174/187152506775268758 (Pubitemid 43796697)
24. Head G. A., Burke S. L., Chan C. K., Site and receptors involved in the sympathoinhibitory actions of rilmenidine. Journal of Hypertension, Supplement 1998 16 3 S7 S12 2-s2.0-0031662170 (Pubitemid 28433254)
25. 2-imidazoline receptors may ameliorate insulin resistance in fructose-rich chow-fed rats. Neuroscience Letters 2008 448 1 90 93 2-s2.0-55749089859 10.1016/j.neulet.2008.10.002
26. Su C. H., Liu I. M., Chung H. H., Cheng J. T., Activation of I2-imidazoline receptors by agmatine improved insulin sensitivity through two mechanisms in type-2 diabetic rats. Neuroscience Letters 2009 457 3 125 128 2-s2.0-67349099607 10.1016/j.neulet.2009.03.093
27. Yang T. T., Ku P. M., Hsu C. T., Chung H. H., Lee W. J., Cheng J. T., Mediation of AMP kinase in the increase of glucose uptake in L6 cells induced by activation of imidazoline I-2 receptors. Hormone and Metabolic Research 2013 10.1055/s-0032-1331184
28. Morgan N. G., Chan S. L. F., Imidazoline binding sites in the endocrine pancreas: can they fulfil their potential as targets for the development of new insulin secretagogues? Current Pharmaceutical Design 2001 7 14 1413 1431 2-s2.0-0034850648 10.2174/1381612013397366 (Pubitemid 32798818)
29. Anderson N. J., Lupo P. A., Nutt D. J., Hudson A. L., Robinson E. S. J., Characterisation of imidazoline I2 binding sites in pig brain. The European Journal of Pharmacology 2005 519 1-2 68 74 2-s2.0-27744457052 10.1016/j.ejphar.2005.06.042 (Pubitemid 43181166)
30. Thomas A. J., Erokwu B. O., Yamamoto B. K., Ernsberger P., Bishara O., Strohl K. P., Alterations in respiratory behavior, brain neurochemistry and receptor density induced by pharmacologic suppression of sleep in the neonatal period. Developmental Brain Research 2000 120 2 181 189 2-s2.0-0034646848 10.1016/S0165-3806(00)00008-0 (Pubitemid 30209910)
31. Zhang J., Abdel-Rahman A. A., Mitogen-activated protein kinase phosphorylation in the rostral ventrolateral medulla plays a key role in imidazoline (I1)-receptor-mediated hypotension. Journal of Pharmacology and Experimental Therapeutics 2005 314 3 945 952 2-s2.0-23944442034 10.1124/jpet.105.087510 (Pubitemid 41205956)
32. Bing C., King P., Pickavance L., Brown M., Ziegler D., Kaan E., Williams G., The effect of moxonidine on feeding and body fat in obese Zucker rats: role of hypothalamic NPY neurones. The British Journal of Pharmacology 1999 127 1 35 42 2-s2.0-0032936546 10.1038/sj.bjp.0702494 (Pubitemid 29213229)
33. Makris A. P., Rush C. R., Frederich R. C., Kelly T. H., Wake-promoting agents with different mechanisms of action: comparison of effects of modafinil and amphetamine on food intake and cardiovascular activity. Appetite 2004 42 2 185 195 2-s2.0-1542298961 10.1016/j.appet.2003.11.003 (Pubitemid 38316889)
34. Matsumura K., Tsuchihashi T., Fujii K., Iida M., Neural regulation of blood pressure by leptin and the related peptides. Regulatory Peptides 2003 114 2-3 79 86 2-s2.0-0038460863 10.1016/S0167-0115(03)00116-2 (Pubitemid 36773870)
35. Wellman P. J., Norepinephrine and the control of food intake. Nutrition 2000 16 10 837 842 2-s2.0-0033776319 10.1016/S0899-9007(00)00415-9
36. Stujii S., Bray G. A., Food intake of lean and obese Zucker rats following ventricular infusions of adrenergic agonists. Brain Research 1992 587 2 226 232 2-s2.0-0026657501 10.1016/0006-8993(92)91001-U
37. Edwards L. P., Brown-Bryan T. A., McLean L., Ernsberger P., Pharmacological properties of the central antihypertensive agent, moxonidine. Cardiovascular Therapeutics 2012 30 4 199 208
38. Panfilov V., Morris A. D., Donnelly R., Scemama M., Reid J. L., The effects of rilmenidine and atenolol on mental stress, dynamic exercise and autonomic function in mild to moderate hypertension. The British Journal of Clinical Pharmacology 1995 40 6 563 569 2-s2.0-0029616371 (Pubitemid 26005561)
39. Yu J. H., Kim M. S., Molecular mechanisms of appetite regulation. Diabetes and Metabolism Journal 2012 36 6 391 398
40. Gallou-Kabani C., Vigé A., Gross M. S., Rabès J. P., Boileau C., Larue-Achagiotis C., Tomé D., Jais J. P., Junien C., C57BL/6J and A/J mice fed a high-fat diet delineate components of metabolic syndrome. Obesity 2007 15 8 1996 2005 2-s2.0-34548614425 10.1038/oby.2007.238 (Pubitemid 47402231)
41. Jéquier E., Leptin signaling, adiposity, and energy balance. Annals of the New York Academy of Sciences 2002 967 379 388 2-s2.0-0036293591 (Pubitemid 34721923)
42. Guan X. M., Yu H., Trumbauer M., Frazier E., van der Ploeg L. H. T., Chen H., Induction of neuropeptide Y expression in dorsomedial hypothalamus of diet-induced obese mice. Neuroreport 1998 9 15 3415 3419 2-s2.0-0032569615 (Pubitemid 28566122)
43. Kim S. O., Yun S. J., Lee E. H., The water extract of adlay seed (Coix lachrymajobi var. mayuen) exhibits anti-obesity effects through neuroendocrine modulation. The American Journal of Chinese Medicine 2007 35 2 297 308 2-s2.0-34147217429 10.1142/S0192415X07004825 (Pubitemid 46579084)
44. Davis R. C., van Nas A., Castellani L. W., Systems genetics of susceptibility to obesity-induced diabetes in mice. Physiological Genomics 2012 44 1 1 13
45. Dhillon S. S., McFadden S. A., Chalmers J. A., Centeno M. L., Kim G. L., Belsham D. D., Cellular leptin resistance impairs the leptin-mediated suppression of neuropeptide Y secretion in hypothalamic neurons. Endocrinology 2011 152 11 4138 4147
46. Jégou S., Boutelet I., Vaudry H., Melanocortin-3 receptor mRNA expression in pro-opiomelanocortin neurones of the rat arcuate nucleus. Journal of Neuroendocrinology 2000 12 6 501 505 2-s2.0-0342804352 10.1046/j.1365-2826. 2000.00477.x (Pubitemid 30311732)
47. Zheng H., Townsend R. L., Shin A. C., Patterson L. M., Phifer C. B., Berthoud H. R., High-fat intake induced by mu-opioid activation of the nucleus accumbens is inhibited by Y1R-blockade and MC3/4R-stimulation. Brain Research 2010 1350 131 138 2-s2.0-77955092398 10.1016/j.brainres.2010.03.061